EICHORCondition: Treatment Resistant Depression · Sponsor: Alar Pharmaceuticals Inc.
This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression (TRD).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Pillar Clinical Research | Little Rock, Arkansas, United States | — |
| Arch Clinical Trials | St Louis, Missouri, United States | — |
| Clinilabs Drug Development Corporation | Eatontown, New Jersey, United States | — |
| Neuro-Behavioral Clinical Research, Inc | North Canton, Ohio, United States | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06965569